AxoGen (AXGN)
(Delayed Data from NSDQ)
$6.63 USD
+0.11 (1.69%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.62 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AXGN 6.63 +0.11(1.69%)
Will AXGN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AXGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXGN
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
Ekso Bionics (EKSO) Reports Q4 Loss, Tops Revenue Estimates
AXGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Must-Buy Stocks for Remarkable Earnings Acceleration
AxoGen (AXGN) Is a Great Choice for 'Trend' Investors, Here's Why
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?
Other News for AXGN
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
AXGN Crosses Below Key Moving Average Level
Director Gregory Freitag Sells 25,000 Shares of Axogen Inc (AXGN)
New Accounting & Financial Operations Risk for AxoGen – What’s the Latest?
AxoGen files $100M mixed securities shelf